Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024
2. 2Supplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024
3. 3Supplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024
4. 4Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024
5. 5Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024